Moderna just released data on the results of its large-scale clinical trial on a COVID-19 vaccine, and the results are something to celebrate; the vaccine demonstrated 94.5% effectiveness with few safety concerns. Similar to the vaccine…

As the number of COVID-19 cases continues to grow rapidly across the United States, mortality rates have steadily decreased, with a 30% drop in deaths seen since April, according to researchers at the University of Washington Institute for…

While many school districts had begun serving students—especially elementary school children—in person this fall, another surge in COVID-19 numbers across the country has led to many schools moving back to virtual learning. Large…

While advanced age and comorbidities are well-known risk factors for severe illness caused by COVID-19, it was still not understood why some people became gravely ill, whereas other patients of similar backgrounds recovered quickly.…

Candida albicans infections in the mouth are often painful for people who develop infections such as burning mouth syndrome or thrush.

United States pharmaceutical giant, Pfizer, whose two-shot COVID-19 vaccine recently showed 90% effectiveness in preliminary studies, is ready to roll out millions of doses as soon as it receives approval from the US Food and Drug…

NYU College of Dentistry (NYU Dentistry) has opened a new dental care practice in Downtown Brooklyn’s City Point. The practice brings high quality, low-cost dental care for adults and children to the Brooklyn community and its surrounding…

As we celebrate our 100th episode of The Art of Dental Finance and Management podcast, Art welcomes Dr. Kathleen O’Loughlin, Executive Director of the American Dental Association (ADA).

A new study found that patients who recovered from COVID-19 were at elevated risk for mental illness. Published in the British medical journal The Lancet, results demonstrated that one in five patients who had recovered from a SARS-CoV-2…

On November 9, the United States Food and Drug Administration issued an emergency use authorization (EUA) to bamlanivimab for the treatment of mild-to-moderate COVID-19. The monoclonal antibody therapy is authorized for COVID-19 patients…